| Participants |
Number of participants: 1000
Age: ≥ 18 years
Gender: male and female
Inclusion criteria
Outpatients with symptomatic laboratory‐proven diagnosis of COVID‐19 (any exam that shows acute infection as positive PCR or IgM in the context of acute symptoms ≤ 10 days) AND Negative pregnancy test for women in childbearing period D‐dimer level ≥ 2 x ULN or C‐reactive protein ≥ 10 mg/L or -
At least 2 of the following risk factors:
D‐dimer level ≥ ULN C‐reactive protein ≥ ULN Age ≥ 65 Diabetes Chronic kidney disease stage 3 Cardiopulmonary disease (e.g. PAD, CAD, heart failure, COPD) History of PE/DVT Nursing home/skilled nursing facility resident or severely restricted mobility BMI ≥ 30 kg/m2
Exclusion criteria
Age < 18 years Patients with indication for full anticoagulation during inclusion (e.g. diagnosis of VTE, atrial fibrillation, MVP) Platelets < 50,000/mm3 Use of acetylsalicylic acid > 100 mg per day Use of P2Y12 inhibitor (clopidogrel, prasugrel, ticagrelor) Chronic use of non‐steroidal anti‐inflammatory drugs Hypersensitivity to apixaban Creatinine clearance < 30 mL/min Pregnancy or breastfeeding Contraindication to anticoagulation (active bleeding, recent major surgery, blood dyscrasia, or prohibitive haemorrhage risk as evaluated by the investigator) A history of haemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous malformation, or aneurysm Use of strong inhibitors of CYP P450 3A4 and/or P‐gp (e.g. protease inhibitors, ketoconazole, itraconazole) and/or use of P‐gp and strong CYP3A4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or St. John's wort)
|
